In a report published Friday, Deutsche Bank analyst Robyn Karnauskas reiterated a Buy rating and $340.00 price target on Biogen Idec BIIB.
In the report, Deutsche Bank noted, “Our calculations on IMS data for Tecfidera for week ending 11/22 indicate strong Tecfidera at $363M-$365M in Q4'13. For FY 2013, our calculations based on IMS data indicate Tecfidera US sales at $839M-$841M. Consensus is expecting 4Q sales at $338M while 2013 sales at $807M in the US. Please ask for our detailed analysis of IMS scripts. Trx were down 1% at 4,967 vs. 5,026 last wk, Nrx were down 3% at 1,805 vs. 1,862 last week.”
Biogen Idec closed on Wednesday at $293.83.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in